nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—MAPK3—ovarian cancer	0.667	1	CbGaD
Sulindac—PTGS2—ovarian follicle—ovarian cancer	0.004	0.0518	CbGeAlD
Sulindac—PTGDR2—female reproductive system—ovarian cancer	0.00328	0.0424	CbGeAlD
Sulindac—AKR1B1—myometrium—ovarian cancer	0.00299	0.0387	CbGeAlD
Sulindac—AKR1B1—embryo—ovarian cancer	0.00287	0.0372	CbGeAlD
Sulindac—AKR1B1—epithelium—ovarian cancer	0.00234	0.0304	CbGeAlD
Sulindac—AKR1B1—uterine cervix—ovarian cancer	0.00232	0.0301	CbGeAlD
Sulindac—AKR1B1—decidua—ovarian cancer	0.00222	0.0287	CbGeAlD
Sulindac—MAPK3—myometrium—ovarian cancer	0.00217	0.028	CbGeAlD
Sulindac—AKR1B1—endometrium—ovarian cancer	0.0021	0.0272	CbGeAlD
Sulindac—MAPK3—embryo—ovarian cancer	0.00208	0.027	CbGeAlD
Sulindac—AKR1B1—gonad—ovarian cancer	0.00195	0.0253	CbGeAlD
Sulindac—AKR1B1—uterus—ovarian cancer	0.00194	0.0251	CbGeAlD
Sulindac—PTGS1—oviduct—ovarian cancer	0.00184	0.0238	CbGeAlD
Sulindac—PPARD—uterine cervix—ovarian cancer	0.00183	0.0237	CbGeAlD
Sulindac—AKR1B1—female reproductive system—ovarian cancer	0.00174	0.0226	CbGeAlD
Sulindac—PPARD—decidua—ovarian cancer	0.00174	0.0226	CbGeAlD
Sulindac—MAPK3—epithelium—ovarian cancer	0.0017	0.022	CbGeAlD
Sulindac—MAPK3—uterine cervix—ovarian cancer	0.00169	0.0218	CbGeAlD
Sulindac—AKR1B1—bone marrow—ovarian cancer	0.00164	0.0213	CbGeAlD
Sulindac—MAPK3—decidua—ovarian cancer	0.00161	0.0208	CbGeAlD
Sulindac—AKR1B1—female gonad—ovarian cancer	0.00159	0.0205	CbGeAlD
Sulindac—AKR1B1—vagina—ovarian cancer	0.00158	0.0204	CbGeAlD
Sulindac—MAPK3—endometrium—ovarian cancer	0.00152	0.0197	CbGeAlD
Sulindac—MAPK3—gonad—ovarian cancer	0.00141	0.0183	CbGeAlD
Sulindac—AKR1B1—testis—ovarian cancer	0.00141	0.0182	CbGeAlD
Sulindac—MAPK3—uterus—ovarian cancer	0.0014	0.0182	CbGeAlD
Sulindac—PPARD—female reproductive system—ovarian cancer	0.00137	0.0177	CbGeAlD
Sulindac—MAPK3—female reproductive system—ovarian cancer	0.00126	0.0164	CbGeAlD
Sulindac—PPARD—female gonad—ovarian cancer	0.00125	0.0161	CbGeAlD
Sulindac—PPARD—vagina—ovarian cancer	0.00124	0.016	CbGeAlD
Sulindac—MAPK3—bone marrow—ovarian cancer	0.00119	0.0154	CbGeAlD
Sulindac—MAPK3—female gonad—ovarian cancer	0.00115	0.0149	CbGeAlD
Sulindac—MAPK3—vagina—ovarian cancer	0.00114	0.0148	CbGeAlD
Sulindac—PPARD—testis—ovarian cancer	0.00111	0.0143	CbGeAlD
Sulindac—MAPK3—testis—ovarian cancer	0.00102	0.0132	CbGeAlD
Sulindac—AKR1B1—lymph node—ovarian cancer	0.00102	0.0132	CbGeAlD
Sulindac—PPARD—lymph node—ovarian cancer	0.000801	0.0104	CbGeAlD
Sulindac—MAPK3—lymph node—ovarian cancer	0.000739	0.00957	CbGeAlD
Sulindac—PTGS2—myometrium—ovarian cancer	0.000563	0.00728	CbGeAlD
Sulindac—PTGS2—embryo—ovarian cancer	0.000541	0.00701	CbGeAlD
Sulindac—CYP1A1—epithelium—ovarian cancer	0.000526	0.00681	CbGeAlD
Sulindac—CYP1A1—uterine cervix—ovarian cancer	0.000521	0.00675	CbGeAlD
Sulindac—ALB—testis—ovarian cancer	0.000486	0.00629	CbGeAlD
Sulindac—PTGS1—epithelium—ovarian cancer	0.000462	0.00598	CbGeAlD
Sulindac—PTGS1—uterine cervix—ovarian cancer	0.000458	0.00593	CbGeAlD
Sulindac—PTGS2—epithelium—ovarian cancer	0.000442	0.00572	CbGeAlD
Sulindac—PTGS2—uterine cervix—ovarian cancer	0.000438	0.00567	CbGeAlD
Sulindac—CYP1A1—uterus—ovarian cancer	0.000435	0.00563	CbGeAlD
Sulindac—PTGS1—endometrium—ovarian cancer	0.000414	0.00536	CbGeAlD
Sulindac—PTGS2—endometrium—ovarian cancer	0.000396	0.00513	CbGeAlD
Sulindac—CYP1A1—female reproductive system—ovarian cancer	0.000391	0.00506	CbGeAlD
Sulindac—PTGS1—uterus—ovarian cancer	0.000382	0.00494	CbGeAlD
Sulindac—PTGS2—uterus—ovarian cancer	0.000365	0.00472	CbGeAlD
Sulindac—CYP1A1—female gonad—ovarian cancer	0.000355	0.0046	CbGeAlD
Sulindac—CYP1A1—vagina—ovarian cancer	0.000353	0.00457	CbGeAlD
Sulindac—ALB—lymph node—ovarian cancer	0.000352	0.00456	CbGeAlD
Sulindac—PTGS1—female reproductive system—ovarian cancer	0.000343	0.00444	CbGeAlD
Sulindac—PTGS2—female reproductive system—ovarian cancer	0.000328	0.00425	CbGeAlD
Sulindac—PTGS1—female gonad—ovarian cancer	0.000312	0.00404	CbGeAlD
Sulindac—PTGS1—vagina—ovarian cancer	0.00031	0.00402	CbGeAlD
Sulindac—PTGS2—bone marrow—ovarian cancer	0.00031	0.00401	CbGeAlD
Sulindac—PTGS2—female gonad—ovarian cancer	0.000298	0.00386	CbGeAlD
Sulindac—PTGS2—vagina—ovarian cancer	0.000297	0.00384	CbGeAlD
Sulindac—PTGS1—testis—ovarian cancer	0.000277	0.00359	CbGeAlD
Sulindac—CYP1A1—lymph node—ovarian cancer	0.000229	0.00296	CbGeAlD
Sulindac—PTGS1—lymph node—ovarian cancer	0.000201	0.0026	CbGeAlD
Sulindac—PTGS2—lymph node—ovarian cancer	0.000192	0.00248	CbGeAlD
Sulindac—Dermatitis—Melphalan—ovarian cancer	0.000145	0.00128	CcSEcCtD
Sulindac—Chills—Docetaxel—ovarian cancer	0.000145	0.00128	CcSEcCtD
Sulindac—Asthenia—Vinorelbine—ovarian cancer	0.000145	0.00127	CcSEcCtD
Sulindac—Arrhythmia—Docetaxel—ovarian cancer	0.000144	0.00127	CcSEcCtD
Sulindac—Convulsion—Paclitaxel—ovarian cancer	0.000144	0.00126	CcSEcCtD
Sulindac—Hypertension—Paclitaxel—ovarian cancer	0.000143	0.00126	CcSEcCtD
Sulindac—Alopecia—Docetaxel—ovarian cancer	0.000143	0.00126	CcSEcCtD
Sulindac—Pruritus—Vinorelbine—ovarian cancer	0.000143	0.00125	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—ovarian cancer	0.000142	0.00125	CcSEcCtD
Sulindac—Chest pain—Paclitaxel—ovarian cancer	0.000141	0.00124	CcSEcCtD
Sulindac—Myalgia—Paclitaxel—ovarian cancer	0.000141	0.00124	CcSEcCtD
Sulindac—Arthralgia—Paclitaxel—ovarian cancer	0.000141	0.00124	CcSEcCtD
Sulindac—Nausea—Topotecan—ovarian cancer	0.00014	0.00123	CcSEcCtD
Sulindac—Discomfort—Paclitaxel—ovarian cancer	0.00014	0.00123	CcSEcCtD
Sulindac—Gastritis—Epirubicin—ovarian cancer	0.00014	0.00123	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—ovarian cancer	0.000139	0.00122	CcSEcCtD
Sulindac—Diarrhoea—Vinorelbine—ovarian cancer	0.000138	0.00121	CcSEcCtD
Sulindac—Dysgeusia—Docetaxel—ovarian cancer	0.000138	0.00121	CcSEcCtD
Sulindac—Nausea—Melphalan—ovarian cancer	0.000137	0.0012	CcSEcCtD
Sulindac—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000136	0.00119	CcSEcCtD
Sulindac—Oedema—Paclitaxel—ovarian cancer	0.000136	0.00119	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—ovarian cancer	0.000135	0.00119	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—ovarian cancer	0.000134	0.00117	CcSEcCtD
Sulindac—Shock—Paclitaxel—ovarian cancer	0.000133	0.00117	CcSEcCtD
Sulindac—Dizziness—Vinorelbine—ovarian cancer	0.000133	0.00117	CcSEcCtD
Sulindac—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000133	0.00117	CcSEcCtD
Sulindac—Tachycardia—Paclitaxel—ovarian cancer	0.000132	0.00116	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—ovarian cancer	0.000131	0.00115	CcSEcCtD
Sulindac—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000131	0.00115	CcSEcCtD
Sulindac—Anaemia—Docetaxel—ovarian cancer	0.00013	0.00114	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—ovarian cancer	0.000129	0.00114	CcSEcCtD
Sulindac—Anorexia—Paclitaxel—ovarian cancer	0.000129	0.00114	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—ovarian cancer	0.000129	0.00113	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—ovarian cancer	0.000129	0.00113	CcSEcCtD
Sulindac—Vomiting—Vinorelbine—ovarian cancer	0.000128	0.00113	CcSEcCtD
Sulindac—Dysuria—Epirubicin—ovarian cancer	0.000127	0.00112	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—ovarian cancer	0.000127	0.00112	CcSEcCtD
Sulindac—Rash—Vinorelbine—ovarian cancer	0.000127	0.00112	CcSEcCtD
Sulindac—Dermatitis—Vinorelbine—ovarian cancer	0.000127	0.00112	CcSEcCtD
Sulindac—Hypotension—Paclitaxel—ovarian cancer	0.000127	0.00111	CcSEcCtD
Sulindac—Headache—Vinorelbine—ovarian cancer	0.000126	0.00111	CcSEcCtD
Sulindac—Syncope—Docetaxel—ovarian cancer	0.000126	0.00111	CcSEcCtD
Sulindac—Leukopenia—Docetaxel—ovarian cancer	0.000126	0.00111	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—ovarian cancer	0.000125	0.0011	CcSEcCtD
Sulindac—Palpitations—Docetaxel—ovarian cancer	0.000124	0.00109	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000124	0.00109	CcSEcCtD
Sulindac—Loss of consciousness—Docetaxel—ovarian cancer	0.000124	0.00109	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—ovarian cancer	0.000124	0.00109	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000123	0.00109	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—ovarian cancer	0.000123	0.00108	CcSEcCtD
Sulindac—Insomnia—Paclitaxel—ovarian cancer	0.000123	0.00108	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—ovarian cancer	0.000122	0.00107	CcSEcCtD
Sulindac—Convulsion—Docetaxel—ovarian cancer	0.000122	0.00107	CcSEcCtD
Sulindac—Paraesthesia—Paclitaxel—ovarian cancer	0.000122	0.00107	CcSEcCtD
Sulindac—Hypertension—Docetaxel—ovarian cancer	0.000122	0.00107	CcSEcCtD
Sulindac—Dyspnoea—Paclitaxel—ovarian cancer	0.000121	0.00106	CcSEcCtD
Sulindac—Somnolence—Paclitaxel—ovarian cancer	0.00012	0.00106	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.00012	0.00106	CcSEcCtD
Sulindac—Chest pain—Docetaxel—ovarian cancer	0.00012	0.00105	CcSEcCtD
Sulindac—Arthralgia—Docetaxel—ovarian cancer	0.00012	0.00105	CcSEcCtD
Sulindac—Myalgia—Docetaxel—ovarian cancer	0.00012	0.00105	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—ovarian cancer	0.00012	0.00105	CcSEcCtD
Sulindac—Nausea—Vinorelbine—ovarian cancer	0.00012	0.00105	CcSEcCtD
Sulindac—Renal failure—Epirubicin—ovarian cancer	0.000119	0.00105	CcSEcCtD
Sulindac—Dyspepsia—Paclitaxel—ovarian cancer	0.000119	0.00105	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000119	0.00105	CcSEcCtD
Sulindac—Jaundice—Epirubicin—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Decreased appetite—Paclitaxel—ovarian cancer	0.000118	0.00104	CcSEcCtD
Sulindac—Fatigue—Paclitaxel—ovarian cancer	0.000117	0.00103	CcSEcCtD
Sulindac—Sweating—Epirubicin—ovarian cancer	0.000116	0.00102	CcSEcCtD
Sulindac—Constipation—Paclitaxel—ovarian cancer	0.000116	0.00102	CcSEcCtD
Sulindac—Haematuria—Epirubicin—ovarian cancer	0.000116	0.00102	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000115	0.00101	CcSEcCtD
Sulindac—Oedema—Docetaxel—ovarian cancer	0.000115	0.00101	CcSEcCtD
Sulindac—Anaphylactic shock—Docetaxel—ovarian cancer	0.000115	0.00101	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—ovarian cancer	0.000115	0.00101	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000114	0.001	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—ovarian cancer	0.000113	0.000997	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—ovarian cancer	0.000113	0.000994	CcSEcCtD
Sulindac—Shock—Docetaxel—ovarian cancer	0.000113	0.000993	CcSEcCtD
Sulindac—Thrombocytopenia—Docetaxel—ovarian cancer	0.000112	0.000989	CcSEcCtD
Sulindac—Tachycardia—Docetaxel—ovarian cancer	0.000112	0.000986	CcSEcCtD
Sulindac—Feeling abnormal—Paclitaxel—ovarian cancer	0.000112	0.000982	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000111	0.00098	CcSEcCtD
Sulindac—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000111	0.000974	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—ovarian cancer	0.00011	0.000971	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.00011	0.000969	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—ovarian cancer	0.00011	0.000963	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—ovarian cancer	0.00011	0.000963	CcSEcCtD
Sulindac—Anorexia—Docetaxel—ovarian cancer	0.000109	0.000963	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—ovarian cancer	0.000109	0.00096	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—ovarian cancer	0.000109	0.000959	CcSEcCtD
Sulindac—Sweating—Doxorubicin—ovarian cancer	0.000108	0.000947	CcSEcCtD
Sulindac—Urticaria—Paclitaxel—ovarian cancer	0.000108	0.000946	CcSEcCtD
Sulindac—Hypotension—Docetaxel—ovarian cancer	0.000107	0.000944	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—ovarian cancer	0.000107	0.000942	CcSEcCtD
Sulindac—Body temperature increased—Paclitaxel—ovarian cancer	0.000107	0.000942	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—ovarian cancer	0.000106	0.000932	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—ovarian cancer	0.000105	0.000924	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—ovarian cancer	0.000105	0.000922	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000105	0.00092	CcSEcCtD
Sulindac—Insomnia—Docetaxel—ovarian cancer	0.000104	0.000913	CcSEcCtD
Sulindac—Paraesthesia—Docetaxel—ovarian cancer	0.000103	0.000907	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—ovarian cancer	0.000103	0.000906	CcSEcCtD
Sulindac—Dyspnoea—Docetaxel—ovarian cancer	0.000102	0.0009	CcSEcCtD
Sulindac—Somnolence—Docetaxel—ovarian cancer	0.000102	0.000898	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—ovarian cancer	0.000102	0.000894	CcSEcCtD
Sulindac—Flushing—Epirubicin—ovarian cancer	0.000101	0.00089	CcSEcCtD
Sulindac—Dyspepsia—Docetaxel—ovarian cancer	0.000101	0.000889	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—ovarian cancer	0.000101	0.000887	CcSEcCtD
Sulindac—Decreased appetite—Docetaxel—ovarian cancer	9.99e-05	0.000878	CcSEcCtD
Sulindac—Hypersensitivity—Paclitaxel—ovarian cancer	9.98e-05	0.000878	CcSEcCtD
Sulindac—Fatigue—Docetaxel—ovarian cancer	9.9e-05	0.000871	CcSEcCtD
Sulindac—Constipation—Docetaxel—ovarian cancer	9.82e-05	0.000864	CcSEcCtD
Sulindac—Chills—Epirubicin—ovarian cancer	9.79e-05	0.00086	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—ovarian cancer	9.74e-05	0.000856	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—ovarian cancer	9.72e-05	0.000855	CcSEcCtD
Sulindac—Asthenia—Paclitaxel—ovarian cancer	9.72e-05	0.000855	CcSEcCtD
Sulindac—Alopecia—Epirubicin—ovarian cancer	9.64e-05	0.000847	CcSEcCtD
Sulindac—Pruritus—Paclitaxel—ovarian cancer	9.59e-05	0.000843	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—ovarian cancer	9.54e-05	0.000839	CcSEcCtD
Sulindac—Feeling abnormal—Docetaxel—ovarian cancer	9.47e-05	0.000832	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—ovarian cancer	9.41e-05	0.000827	CcSEcCtD
Sulindac—Gastrointestinal pain—Docetaxel—ovarian cancer	9.39e-05	0.000826	CcSEcCtD
Sulindac—Flushing—Doxorubicin—ovarian cancer	9.36e-05	0.000823	CcSEcCtD
Sulindac—Flatulence—Epirubicin—ovarian cancer	9.35e-05	0.000822	CcSEcCtD
Sulindac—Tension—Epirubicin—ovarian cancer	9.32e-05	0.000819	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—ovarian cancer	9.3e-05	0.000817	CcSEcCtD
Sulindac—Diarrhoea—Paclitaxel—ovarian cancer	9.27e-05	0.000815	CcSEcCtD
Sulindac—Nervousness—Epirubicin—ovarian cancer	9.22e-05	0.000811	CcSEcCtD
Sulindac—Body temperature increased—Docetaxel—ovarian cancer	9.08e-05	0.000798	CcSEcCtD
Sulindac—Chills—Doxorubicin—ovarian cancer	9.05e-05	0.000796	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—ovarian cancer	9.01e-05	0.000792	CcSEcCtD
Sulindac—Dizziness—Paclitaxel—ovarian cancer	8.96e-05	0.000788	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—ovarian cancer	8.95e-05	0.000786	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—ovarian cancer	8.92e-05	0.000784	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—ovarian cancer	8.81e-05	0.000774	CcSEcCtD
Sulindac—Anaemia—Epirubicin—ovarian cancer	8.77e-05	0.000771	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—ovarian cancer	8.66e-05	0.000761	CcSEcCtD
Sulindac—Tension—Doxorubicin—ovarian cancer	8.62e-05	0.000758	CcSEcCtD
Sulindac—Vomiting—Paclitaxel—ovarian cancer	8.62e-05	0.000757	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—ovarian cancer	8.6e-05	0.000756	CcSEcCtD
Sulindac—Malaise—Epirubicin—ovarian cancer	8.56e-05	0.000753	CcSEcCtD
Sulindac—Rash—Paclitaxel—ovarian cancer	8.54e-05	0.000751	CcSEcCtD
Sulindac—Dermatitis—Paclitaxel—ovarian cancer	8.54e-05	0.00075	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—ovarian cancer	8.53e-05	0.00075	CcSEcCtD
Sulindac—Vertigo—Epirubicin—ovarian cancer	8.53e-05	0.00075	CcSEcCtD
Sulindac—Syncope—Epirubicin—ovarian cancer	8.51e-05	0.000748	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—ovarian cancer	8.5e-05	0.000747	CcSEcCtD
Sulindac—Headache—Paclitaxel—ovarian cancer	8.49e-05	0.000746	CcSEcCtD
Sulindac—Hypersensitivity—Docetaxel—ovarian cancer	8.46e-05	0.000744	CcSEcCtD
Sulindac—Palpitations—Epirubicin—ovarian cancer	8.39e-05	0.000737	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—ovarian cancer	8.34e-05	0.000733	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—ovarian cancer	8.28e-05	0.000728	CcSEcCtD
Sulindac—Asthenia—Docetaxel—ovarian cancer	8.24e-05	0.000724	CcSEcCtD
Sulindac—Convulsion—Epirubicin—ovarian cancer	8.23e-05	0.000723	CcSEcCtD
Sulindac—Hypertension—Epirubicin—ovarian cancer	8.2e-05	0.000721	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—ovarian cancer	8.15e-05	0.000716	CcSEcCtD
Sulindac—Pruritus—Docetaxel—ovarian cancer	8.13e-05	0.000714	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—ovarian cancer	8.12e-05	0.000714	CcSEcCtD
Sulindac—Chest pain—Epirubicin—ovarian cancer	8.08e-05	0.00071	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—ovarian cancer	8.08e-05	0.00071	CcSEcCtD
Sulindac—Myalgia—Epirubicin—ovarian cancer	8.08e-05	0.00071	CcSEcCtD
Sulindac—Nausea—Paclitaxel—ovarian cancer	8.05e-05	0.000708	CcSEcCtD
Sulindac—Discomfort—Epirubicin—ovarian cancer	7.99e-05	0.000702	CcSEcCtD
Sulindac—Malaise—Doxorubicin—ovarian cancer	7.92e-05	0.000696	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—ovarian cancer	7.89e-05	0.000694	CcSEcCtD
Sulindac—Syncope—Doxorubicin—ovarian cancer	7.88e-05	0.000692	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—ovarian cancer	7.86e-05	0.000691	CcSEcCtD
Sulindac—Diarrhoea—Docetaxel—ovarian cancer	7.86e-05	0.000691	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—ovarian cancer	7.76e-05	0.000682	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—ovarian cancer	7.75e-05	0.000681	CcSEcCtD
Sulindac—Oedema—Epirubicin—ovarian cancer	7.75e-05	0.000681	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—ovarian cancer	7.72e-05	0.000679	CcSEcCtD
Sulindac—Shock—Epirubicin—ovarian cancer	7.62e-05	0.00067	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—ovarian cancer	7.61e-05	0.000669	CcSEcCtD
Sulindac—Dizziness—Docetaxel—ovarian cancer	7.6e-05	0.000668	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—ovarian cancer	7.59e-05	0.000667	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—ovarian cancer	7.58e-05	0.000667	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—ovarian cancer	7.56e-05	0.000665	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—ovarian cancer	7.49e-05	0.000658	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—ovarian cancer	7.48e-05	0.000657	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—ovarian cancer	7.48e-05	0.000657	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—ovarian cancer	7.48e-05	0.000657	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—ovarian cancer	7.39e-05	0.00065	CcSEcCtD
Sulindac—Anorexia—Epirubicin—ovarian cancer	7.39e-05	0.000649	CcSEcCtD
Sulindac—Vomiting—Docetaxel—ovarian cancer	7.3e-05	0.000642	CcSEcCtD
Sulindac—Rash—Docetaxel—ovarian cancer	7.24e-05	0.000637	CcSEcCtD
Sulindac—Hypotension—Epirubicin—ovarian cancer	7.24e-05	0.000636	CcSEcCtD
Sulindac—Dermatitis—Docetaxel—ovarian cancer	7.24e-05	0.000636	CcSEcCtD
Sulindac—Headache—Docetaxel—ovarian cancer	7.2e-05	0.000633	CcSEcCtD
Sulindac—Oedema—Doxorubicin—ovarian cancer	7.17e-05	0.00063	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—ovarian cancer	7.17e-05	0.00063	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—ovarian cancer	7.06e-05	0.000621	CcSEcCtD
Sulindac—Shock—Doxorubicin—ovarian cancer	7.05e-05	0.00062	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—ovarian cancer	7.02e-05	0.000617	CcSEcCtD
Sulindac—Insomnia—Epirubicin—ovarian cancer	7.01e-05	0.000616	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—ovarian cancer	7e-05	0.000615	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—ovarian cancer	6.96e-05	0.000612	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—ovarian cancer	6.93e-05	0.000609	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—ovarian cancer	6.91e-05	0.000607	CcSEcCtD
Sulindac—Somnolence—Epirubicin—ovarian cancer	6.89e-05	0.000605	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—ovarian cancer	6.83e-05	0.000601	CcSEcCtD
Sulindac—Nausea—Docetaxel—ovarian cancer	6.82e-05	0.0006	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—ovarian cancer	6.82e-05	0.0006	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—ovarian cancer	6.74e-05	0.000592	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—ovarian cancer	6.7e-05	0.000589	CcSEcCtD
Sulindac—Fatigue—Epirubicin—ovarian cancer	6.68e-05	0.000587	CcSEcCtD
Sulindac—Constipation—Epirubicin—ovarian cancer	6.63e-05	0.000582	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	6.53e-05	0.000574	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—ovarian cancer	6.48e-05	0.00057	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—ovarian cancer	6.44e-05	0.000566	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—ovarian cancer	6.39e-05	0.000562	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—ovarian cancer	6.38e-05	0.000561	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—ovarian cancer	6.37e-05	0.00056	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—ovarian cancer	6.34e-05	0.000557	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—ovarian cancer	6.31e-05	0.000555	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—ovarian cancer	6.23e-05	0.000548	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—ovarian cancer	6.18e-05	0.000543	CcSEcCtD
Sulindac—Urticaria—Epirubicin—ovarian cancer	6.16e-05	0.000541	CcSEcCtD
Sulindac—Constipation—Doxorubicin—ovarian cancer	6.13e-05	0.000539	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—ovarian cancer	6.12e-05	0.000538	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—ovarian cancer	5.91e-05	0.000519	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.86e-05	0.000515	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—ovarian cancer	5.71e-05	0.000502	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—ovarian cancer	5.7e-05	0.000501	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—ovarian cancer	5.67e-05	0.000498	CcSEcCtD
Sulindac—Asthenia—Epirubicin—ovarian cancer	5.56e-05	0.000489	CcSEcCtD
Sulindac—Pruritus—Epirubicin—ovarian cancer	5.48e-05	0.000482	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—ovarian cancer	5.3e-05	0.000466	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—ovarian cancer	5.28e-05	0.000464	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—ovarian cancer	5.14e-05	0.000452	CcSEcCtD
Sulindac—Dizziness—Epirubicin—ovarian cancer	5.12e-05	0.00045	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—ovarian cancer	5.07e-05	0.000446	CcSEcCtD
Sulindac—Vomiting—Epirubicin—ovarian cancer	4.93e-05	0.000433	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—ovarian cancer	4.91e-05	0.000431	CcSEcCtD
Sulindac—Rash—Epirubicin—ovarian cancer	4.89e-05	0.000429	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—ovarian cancer	4.88e-05	0.000429	CcSEcCtD
Sulindac—Headache—Epirubicin—ovarian cancer	4.85e-05	0.000427	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—ovarian cancer	4.74e-05	0.000417	CcSEcCtD
Sulindac—Nausea—Epirubicin—ovarian cancer	4.6e-05	0.000405	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—ovarian cancer	4.56e-05	0.000401	CcSEcCtD
Sulindac—Rash—Doxorubicin—ovarian cancer	4.52e-05	0.000397	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—ovarian cancer	4.52e-05	0.000397	CcSEcCtD
Sulindac—Headache—Doxorubicin—ovarian cancer	4.49e-05	0.000395	CcSEcCtD
Sulindac—Nausea—Doxorubicin—ovarian cancer	4.26e-05	0.000374	CcSEcCtD
Sulindac—ALB—Hemostasis—CAV1—ovarian cancer	1.05e-05	7.36e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYTB—ovarian cancer	1.05e-05	7.36e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	1.05e-05	7.36e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.05e-05	7.35e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTEN—ovarian cancer	1.04e-05	7.32e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.04e-05	7.28e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—ovarian cancer	1.03e-05	7.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—ovarian cancer	1.03e-05	7.22e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.02e-05	7.19e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CYP1B1—ovarian cancer	1.01e-05	7.13e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—ovarian cancer	1.01e-05	7.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—ovarian cancer	1.01e-05	7.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MAPK1—ovarian cancer	1.01e-05	7.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PPP2R1A—ovarian cancer	1e-05	7.06e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC2A1—ovarian cancer	1e-05	7.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CD—ovarian cancer	1e-05	7.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6ST—ovarian cancer	9.99e-06	7.02e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	9.96e-06	7e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	9.81e-06	6.89e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—ovarian cancer	9.69e-06	6.81e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—YAP1—ovarian cancer	9.62e-06	6.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MAPK1—ovarian cancer	9.61e-06	6.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—EGFR—ovarian cancer	9.6e-06	6.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—APC—ovarian cancer	9.6e-06	6.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDH1—ovarian cancer	9.56e-06	6.72e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CG—ovarian cancer	9.54e-06	6.7e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.53e-06	6.7e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	9.52e-06	6.69e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.43e-06	6.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—ovarian cancer	9.26e-06	6.51e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BRIP1—ovarian cancer	9.15e-06	6.43e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPP1CC—ovarian cancer	9.15e-06	6.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CD—ovarian cancer	9.14e-06	6.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—ovarian cancer	9.07e-06	6.38e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPP2R1A—ovarian cancer	8.99e-06	6.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—ovarian cancer	8.96e-06	6.3e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	8.95e-06	6.29e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—ovarian cancer	8.94e-06	6.28e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—FASN—ovarian cancer	8.84e-06	6.21e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—YAP1—ovarian cancer	8.77e-06	6.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—ovarian cancer	8.73e-06	6.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CB—ovarian cancer	8.72e-06	6.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC5A5—ovarian cancer	8.69e-06	6.11e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.68e-06	6.1e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	8.64e-06	6.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—ovarian cancer	8.57e-06	6.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PPP2R1A—ovarian cancer	8.53e-06	5.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—ovarian cancer	8.45e-06	5.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CD—ovarian cancer	8.44e-06	5.93e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC2A1—ovarian cancer	8.4e-06	5.9e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CD—ovarian cancer	8.38e-06	5.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL8—ovarian cancer	8.38e-06	5.89e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	8.37e-06	5.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—ovarian cancer	8.36e-06	5.87e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ABCB1—ovarian cancer	8.35e-06	5.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—ovarian cancer	8.34e-06	5.86e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	8.22e-06	5.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TYMS—ovarian cancer	8.2e-06	5.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—ovarian cancer	8.07e-06	5.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP1B1—ovarian cancer	8.05e-06	5.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—ovarian cancer	8e-06	5.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TERT—ovarian cancer	7.98e-06	5.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MTOR—ovarian cancer	7.96e-06	5.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CB—ovarian cancer	7.96e-06	5.6e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—FASN—ovarian cancer	7.85e-06	5.51e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—ovarian cancer	7.72e-06	5.43e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC5A5—ovarian cancer	7.72e-06	5.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—ovarian cancer	7.71e-06	5.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—ovarian cancer	7.71e-06	5.42e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.63e-06	5.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—ovarian cancer	7.56e-06	5.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDKN1B—ovarian cancer	7.47e-06	5.25e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC2A1—ovarian cancer	7.45e-06	5.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—ovarian cancer	7.45e-06	5.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—ovarian cancer	7.38e-06	5.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CAV1—ovarian cancer	7.38e-06	5.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MTOR—ovarian cancer	7.35e-06	5.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CB—ovarian cancer	7.35e-06	5.17e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—ovarian cancer	7.35e-06	5.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—ovarian cancer	7.31e-06	5.14e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CB—ovarian cancer	7.31e-06	5.14e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.3e-06	5.13e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—FASN—ovarian cancer	7.15e-06	5.03e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP1B1—ovarian cancer	7.15e-06	5.02e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPP2R1A—ovarian cancer	7.14e-06	5.02e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ESR1—ovarian cancer	7.11e-06	5e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	7.11e-06	4.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTNNB1—ovarian cancer	7.06e-06	4.96e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	7.06e-06	4.96e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC5A5—ovarian cancer	7.03e-06	4.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6ST—ovarian cancer	6.99e-06	4.92e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDKN1B—ovarian cancer	6.9e-06	4.85e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—ovarian cancer	6.88e-06	4.84e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—ovarian cancer	6.81e-06	4.79e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC2A1—ovarian cancer	6.79e-06	4.78e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—ovarian cancer	6.77e-06	4.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APC—ovarian cancer	6.72e-06	4.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CG—ovarian cancer	6.72e-06	4.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—ovarian cancer	6.72e-06	4.72e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—ovarian cancer	6.71e-06	4.72e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	6.67e-06	4.69e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.65e-06	4.68e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ABCB1—ovarian cancer	6.63e-06	4.66e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAV1—ovarian cancer	6.61e-06	4.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CTNNB1—ovarian cancer	6.52e-06	4.58e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP1B1—ovarian cancer	6.51e-06	4.58e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TYMS—ovarian cancer	6.51e-06	4.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—ovarian cancer	6.35e-06	4.47e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPP2R1A—ovarian cancer	6.34e-06	4.45e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.31e-06	4.44e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.31e-06	4.43e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CAV1—ovarian cancer	6.26e-06	4.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—ovarian cancer	6.15e-06	4.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—ovarian cancer	6.14e-06	4.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—YAP1—ovarian cancer	6.14e-06	4.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—MAPK1—ovarian cancer	6.12e-06	4.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—ovarian cancer	6.12e-06	4.3e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	6.07e-06	4.27e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—ovarian cancer	6.02e-06	4.23e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—ovarian cancer	6.01e-06	4.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6ST—ovarian cancer	5.94e-06	4.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—ovarian cancer	5.91e-06	4.15e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ABCB1—ovarian cancer	5.88e-06	4.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—ovarian cancer	5.78e-06	4.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TYMS—ovarian cancer	5.78e-06	4.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPP2R1A—ovarian cancer	5.78e-06	4.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.75e-06	4.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—ovarian cancer	5.71e-06	4.01e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—ovarian cancer	5.7e-06	4.01e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—ovarian cancer	5.69e-06	4e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—ovarian cancer	5.68e-06	3.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—ovarian cancer	5.67e-06	3.98e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—ovarian cancer	5.63e-06	3.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK1—ovarian cancer	5.59e-06	3.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—ovarian cancer	5.59e-06	3.93e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK3—ovarian cancer	5.4e-06	3.79e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—ABCB1—ovarian cancer	5.36e-06	3.77e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	5.34e-06	3.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—ovarian cancer	5.31e-06	3.73e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—ovarian cancer	5.29e-06	3.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—ovarian cancer	5.28e-06	3.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—ovarian cancer	5.28e-06	3.71e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—TYMS—ovarian cancer	5.27e-06	3.7e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAV1—ovarian cancer	5.25e-06	3.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—ovarian cancer	5.22e-06	3.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MAPK1—ovarian cancer	5.17e-06	3.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—ovarian cancer	5.16e-06	3.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MTOR—ovarian cancer	5.15e-06	3.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—ovarian cancer	5.15e-06	3.62e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK1—ovarian cancer	5.13e-06	3.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—ovarian cancer	5.02e-06	3.53e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	5.01e-06	3.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—FASN—ovarian cancer	5e-06	3.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—ovarian cancer	4.95e-06	3.48e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—ovarian cancer	4.92e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—ovarian cancer	4.92e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—ovarian cancer	4.88e-06	3.43e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—ovarian cancer	4.85e-06	3.41e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—ovarian cancer	4.85e-06	3.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDKN1B—ovarian cancer	4.83e-06	3.4e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—ovarian cancer	4.78e-06	3.36e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC2A1—ovarian cancer	4.75e-06	3.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—ovarian cancer	4.74e-06	3.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—ovarian cancer	4.73e-06	3.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—ovarian cancer	4.71e-06	3.31e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAV1—ovarian cancer	4.66e-06	3.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	4.65e-06	3.27e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—ovarian cancer	4.61e-06	3.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—ovarian cancer	4.61e-06	3.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CTNNB1—ovarian cancer	4.56e-06	3.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP1B1—ovarian cancer	4.56e-06	3.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—ovarian cancer	4.49e-06	3.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—ovarian cancer	4.48e-06	3.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—ovarian cancer	4.48e-06	3.15e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—ovarian cancer	4.45e-06	3.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—ovarian cancer	4.45e-06	3.13e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.45e-06	3.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—ovarian cancer	4.43e-06	3.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MTOR—ovarian cancer	4.37e-06	3.07e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—ovarian cancer	4.37e-06	3.07e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—ovarian cancer	4.34e-06	3.05e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—ovarian cancer	4.31e-06	3.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—ovarian cancer	4.3e-06	3.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAV1—ovarian cancer	4.24e-06	2.98e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—ovarian cancer	4.24e-06	2.98e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—ovarian cancer	4.2e-06	2.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—ovarian cancer	4.15e-06	2.91e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—ovarian cancer	4.12e-06	2.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN1B—ovarian cancer	4.1e-06	2.88e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.06e-06	2.85e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPP2R1A—ovarian cancer	4.04e-06	2.84e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	4.02e-06	2.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—ovarian cancer	4.02e-06	2.82e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—ovarian cancer	3.99e-06	2.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—ovarian cancer	3.98e-06	2.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—ovarian cancer	3.97e-06	2.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—ovarian cancer	3.97e-06	2.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—ovarian cancer	3.97e-06	2.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—ovarian cancer	3.94e-06	2.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CTNNB1—ovarian cancer	3.88e-06	2.72e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—ovarian cancer	3.87e-06	2.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—ovarian cancer	3.78e-06	2.66e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ABCB1—ovarian cancer	3.75e-06	2.64e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—ovarian cancer	3.73e-06	2.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—ovarian cancer	3.7e-06	2.6e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TYMS—ovarian cancer	3.68e-06	2.59e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—ovarian cancer	3.66e-06	2.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—ovarian cancer	3.66e-06	2.57e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—ovarian cancer	3.64e-06	2.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK1—ovarian cancer	3.62e-06	2.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—ovarian cancer	3.62e-06	2.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—ovarian cancer	3.42e-06	2.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—ovarian cancer	3.4e-06	2.39e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—ovarian cancer	3.38e-06	2.38e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—ovarian cancer	3.37e-06	2.37e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—ovarian cancer	3.25e-06	2.28e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK3—ovarian cancer	3.23e-06	2.27e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—ovarian cancer	3.16e-06	2.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—ovarian cancer	3.14e-06	2.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—ovarian cancer	3.14e-06	2.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK1—ovarian cancer	3.07e-06	2.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—ovarian cancer	3.07e-06	2.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—ovarian cancer	3.04e-06	2.13e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAV1—ovarian cancer	2.97e-06	2.09e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—ovarian cancer	2.96e-06	2.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—ovarian cancer	2.9e-06	2.04e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—ovarian cancer	2.9e-06	2.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.84e-06	1.99e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—ovarian cancer	2.81e-06	1.98e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—ovarian cancer	2.81e-06	1.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—ovarian cancer	2.78e-06	1.95e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—ovarian cancer	2.7e-06	1.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—ovarian cancer	2.67e-06	1.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—ovarian cancer	2.56e-06	1.8e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—ovarian cancer	2.56e-06	1.8e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—ovarian cancer	2.47e-06	1.73e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—ovarian cancer	2.38e-06	1.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—ovarian cancer	2.36e-06	1.66e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—ovarian cancer	2.3e-06	1.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—ovarian cancer	2.23e-06	1.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—ovarian cancer	2.18e-06	1.53e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—ovarian cancer	2.07e-06	1.46e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—ovarian cancer	1.98e-06	1.39e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—ovarian cancer	1.82e-06	1.28e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—ovarian cancer	1.81e-06	1.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—ovarian cancer	1.79e-06	1.26e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—ovarian cancer	1.62e-06	1.14e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—ovarian cancer	1.48e-06	1.04e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.26e-06	8.88e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—ovarian cancer	1.03e-06	7.25e-06	CbGpPWpGaD
